CY1115659T1 - SPECIFIC COMMITMENT TO GROWTH FACTORS - Google Patents

SPECIFIC COMMITMENT TO GROWTH FACTORS

Info

Publication number
CY1115659T1
CY1115659T1 CY20141100892T CY141100892T CY1115659T1 CY 1115659 T1 CY1115659 T1 CY 1115659T1 CY 20141100892 T CY20141100892 T CY 20141100892T CY 141100892 T CY141100892 T CY 141100892T CY 1115659 T1 CY1115659 T1 CY 1115659T1
Authority
CY
Cyprus
Prior art keywords
hgf
growth factors
specific binding
methods
specific commitment
Prior art date
Application number
CY20141100892T
Other languages
Greek (el)
Inventor
Teresa L Burgess
Angela Coxon
Larry L Green
Ke Zhang
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04776560.7A external-priority patent/EP1648998B1/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1115659T1 publication Critical patent/CY1115659T1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Περιγράφονται μέσα ειδικής δέσμευσης, τα οποία αλληλεπιδρούν με τον αυξητικό παράγοντα των ηπατοκυττάρων (HGF). Περιγράφονται μέθοδοι για την αντιμετώπιση του καρκίνου με τη χορήγηση μιας φαρμακευτικά αποτελεσματικής ποσότητας ενός μέσου ειδικής δέσμευσης στον HGF. Περιγράφονται μέθοδοι για την ανίχνευση της ποσότητας του HGF σε ένα δείγμα χρησιμοποιώντας ένα μέσο ειδικής δέσμευσης στον HGF.Specific binding agents are described, which interact with hepatocyte growth factor (HGF). Methods for treating cancer by administering a pharmaceutically effective amount of a specific binding agent to HGF are described. Methods are described for detecting the amount of HGF in a sample using a HGF specific binding medium.

CY20141100892T 2003-07-18 2014-10-30 SPECIFIC COMMITMENT TO GROWTH FACTORS CY1115659T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48868103A 2003-07-18 2003-07-18
EP04776560.7A EP1648998B1 (en) 2003-07-18 2004-07-16 Specific binding agents to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
CY1115659T1 true CY1115659T1 (en) 2017-01-25

Family

ID=58457036

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100892T CY1115659T1 (en) 2003-07-18 2014-10-30 SPECIFIC COMMITMENT TO GROWTH FACTORS

Country Status (1)

Country Link
CY (1) CY1115659T1 (en)

Similar Documents

Publication Publication Date Title
EA200600233A1 (en) SPECIFIC CONNECTING AGENTS, INTERACTING WITH THE GROWTH FACTORS OF HEPATOCYTES
CY1121151T1 (en) ANTIBODIES TO OPGL
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
NO2017019I2 (en) Enzalutamide or a pharmaceutically acceptable salt thereof
CY1117236T1 (en) MONOCLONIC ANTIBODIES AGAINST GLYPICAN-3
EA200802213A1 (en) METHODS OF TREATING BLOOD DISEASES
ES2534303T3 (en) Procedures and compositions involving miRNA and miRNA inhibitor molecules
AR110056A2 (en) MODULATION OF CHEMIOSENSORY AND LIGAND RECEIVERS RELATED TO THEMSELVES
CY1108092T1 (en) UNIONS AND METHODS FOR SUSPENSION OF AURORA CHINESE PROHIBITION
CR10147A (en) "LIGANDOS THAT HAVE SPECIFICITY OF LINK FOR VEGF AND / OR EGFR AND METHODS OF USE OF THE SAME"
DE602005018043D1 (en) LIPOSOMAL FORMULATIONS WITH DIHYDROSPHENOMYLININ AND METHOD FOR THEIR USE
EA200801172A1 (en) LIGANDS HAVING A SPECIFICITY OF BINDING WITH RESPECT TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR (EGFR) AND / OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND THEIR APPLICATION
BRPI0618488A2 (en) Hepatocyte Growth Factor Intron Fusion Proteins
BRPI0510177B8 (en) compound, pharmaceutical composition and use thereof
BRPI0918555A2 (en) antibody, composition, nucleic acid molecule, method of treating a malignant tumor in an animal, and, use of the composition.
DK1629011T3 (en) Human anti-human DC3 binding molecules
NI200600290A (en) PIRAZOL DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE PROCEDURES
ATE336509T1 (en) USE OF TACI AS AN ANTITUMOR AGENT
ATE456666T1 (en) METHOD FOR EVALUATION OF RIBONUCLEOTIDE SEQUENCES
DK1325011T3 (en) Methods and Compounds for the Treatment of Proliferative Diseases
CY1112980T1 (en) PHARMACEUTICAL COMPOSITIONS WHICH HAVE IMPROVED SOLUTION PROFILES FOR SOLUBLE REACTIVE SUBSTANCES
EA200870148A1 (en) SULINDAC DERIVATIVES, THEIR APPLICATION AND RECEIVING
ATE435647T1 (en) RUTHENIUM COMPLEXES FOR CANCER TREATMENT
SE0300457D0 (en) Novel compounds
CY1115659T1 (en) SPECIFIC COMMITMENT TO GROWTH FACTORS